The engineered 4-1BBL molecule has strong structural flexibility, allowing it to optimally engage and cluster with T cells. This material relates to a paper that appeared in the Jun. 19, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by C. Claus at Roche Innovation Center Zurich in Schlieren, Switzerland; and colleagues was titled, "Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy."
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact Science for permission.